On Mar. 14, 2016, Inovio Pharmaceuticals announced an agreement to acquire all of Bioject Medical Technologies’s assets including pioneering needle-free jet injection technology, devices, and intellectual property.

Inovio paid Bioject $4.5 million in Inovio stock (price set by 20 day weighted average share price immediately prior to closing) and $1.0 million in cash. Bioject, founded in 1985, was based in Tigard, Oregon.